CMS unveils preliminary Aduhelm coverage decision

CMS intends for Medicare to cover Aduhelm, Biogen's Alzheimer's disease treatment, for patients taking part in clinical trials, the agency announced Jan. 11. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive